Evidence map›Paper›PMID 25595799›Full record

ReviewProgress in molecular biology and translational science2015

Unity in diversity: shared mechanism of entry among paramyxoviruses.

Jean-Louis Palgen, Eric M Jurgens, Anne Moscona, Matteo Porotto, Laura M Palermo

Abstract readReview
In one paragraph

Review in Progress in molecular biology and translational science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Syncytial therapeutics: Receptor-specific and direct-to-cytosol biologic drug delivery mediated by measles fusion complex.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  2. Article
  3. bioRxiv : the preprint server for biology · 2024
    Article
  4. Isolation and Molecular Characterisation of Respirovirus 3 in Wild Boar.Animals : an open access journal from MDPI · 2023
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jean-Louis PalgenDepartment of Pediatrics, Weill Cornell Medical College, Cornell University, New York, USA; Department of Biology, Ecole Normale Supérieure, Lyon, France.
Eric M JurgensDepartment of Pediatrics, Weill Cornell Medical College, Cornell University, New York, USA.
Anne MosconaDepartment of Pediatrics, Weill Cornell Medical College, Cornell University, New York, USA; Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, USA.
Matteo PorottoDepartment of Pediatrics, Weill Cornell Medical College, Cornell University, New York, USA. Electronic address: map2028@med.cornell.edu.
Laura M PalermoDepartment of Pediatrics, Weill Cornell Medical College, Cornell University, New York, USA; Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, USA.
Cornell University · US

Funding

Viral Pathogenesis and TherapeuticsU54AI057158 · NIAID · WADSWORTH CENTER · PI LEVY, DAVID E · 2003 to 2014
$100.8M
Molecular basis for paramyxovirus entryR01AI031971 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 1998 to 2016
$6.6M
Bioengineering protocells for a new class of viral vaccinesR21EB011707 · NIBIB · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2011 to 2012
$465k
Active and arrested paramyxovirus fusion machinery visualized by cryo-electron toR21AI100292 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2012 to 2013
$435k
Development of therapeutic fusion inhibitor peptides for Measles encephalitisR21NS073781 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2011 to 2012
$420k
NIAID NIH HHS 3R01 AI031971-19S1NIAID NIH HHS R01 AI031971NIAID NIH HHS R01 AI31971NIAID NIH HHS R21 AI100292NIAID NIH HHS U54 AI057158NIAID NIH HHS U54AI057158NIBIB NIH HHS R21 EB011707NIBIB NIH HHS R21EB011707NINDS NIH HHS R21 NS073781
6 · The paper itself

Abstract

The Paramyxoviridae family includes many viruses that are pathogenic in humans, including parainfluenza viruses, measles virus, respiratory syncytial virus, and the emerging zoonotic Henipaviruses. No effective treatments are currently available for these viruses, and there is a need for efficient antiviral therapies. Paramyxoviruses enter the target cell by binding to a cell surface receptor and then fusing the viral envelope with the target cell membrane, allowing the release of the viral genome into the cytoplasm. Blockage of these crucial steps prevents infection and disease. Binding and fusion are driven by two virus-encoded glycoproteins, the receptor-binding protein and the fusion protein, that together form the viral "fusion machinery." The development of efficient antiviral drugs requires a deeper understanding of the mechanism of action of the Paramyxoviridae fusion machinery, which is still controversial. Here, we review recent structural and functional data on these proteins and the current understanding of the mechanism of the paramyxovirus cell entry process.

Indexed as

Virus InternalizationAnimalsGlycoproteinsHumansParamyxoviridaeProtein BindingReceptors, Cell SurfaceViral ProteinsGlycoproteinsReceptors, Cell SurfaceViral ProteinsFusion machineryFusion proteinParamyxoviridaeReceptor-binding proteinViral entry

Identifiers

PMID25595799
PMCPMC4369139
OpenAlexW2405325856

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.